Amicus Therapeutics is a Cranbury, New Jersey-based public biotechnology company that has over the past years been the vanguard in the fight against rare and orphan diseases by using therapies. Founded on 4th February, 2002, Amicus Therapeutics has always envisaged having a positive impact in the lives of ailing patients by providing the most effective therapies for them. Essentially, their inventive science, clinical programs, and commercial organization are directed towards satisfying the needs of patients.
Equipped with state-of-the-art equipment and medicine, Amicus Therapeutics has been able to provide the requisite healthcare for patients suffering from ailments such as Fabry and Pompe diseases and genetic connective skin disorders. The products offered by Amicus Therapeutics are generally hinged upon the Chaperone-Advanced Replacement Therapy, popularly referred to as CHART, that encompasses a series of therapies that seek to replace the patients’ body enzymes.
One of the most outstanding products made by Amicus Therapeutics is known as Migalasat; this is a drug that is used to treat patients who have shown symptoms of Fabry disease (BlogWebPedia). Another product that Amicus Therapeutics have developed over the past few years is known as SD-101. SD-101 is a therapy that would treat patients with Epidermolysis Bullosa (EB), a genetic connective tissue disorder.
Amicus Therapeutics has undergone an immense deal of growth and development since its inception, and most of the growth can actually be attributed to the company’s leadership. At the helm of the company is John F. Crowley who serves as the Chairman. Under his remarkable leadership that has spanned over a decade, Amicus Therapeutics expanded and set up another research site in San Diego, California.
Amicus Therapeutics is undoubtedly one of the most iconic institutions in the American Therapeutic industry that have shown patients with rare and orphan diseases light at the end of the tunnel. Their incredible scientific and medical advancements have given whispers of hope to such patients as they are now able to get effective medical remedies for their ailments.
More about Amicus Therapeutics at https://www.google.com/finance?cid=706165